The Platelet Activating Factor (PAF) Signaling Cascade in Systemic Inflammatory Responses

Overview

Journal Biochimie

Specialty Biochemistry

Date 2010 Feb 20

PMID 20167241

Citations 64

Authors

Christian C Yost

Andrew S Weyrich

Guy A Zimmerman

Affiliations

Soon will be listed here.

Abstract

The platelet-activating factor (PAF) signaling cascade evolved as a component of the repertoire of innate host defenses, but is also an effector pathway in inflammatory and thrombotic diseases. This review focuses on the PAF signaling cascade in systemic inflammatory responses and, specifically, explores its activities in experimental and clinical sepsis and anaphylaxis in the context of the basic biochemistry and biology of signaling via this lipid mediator system.

Citing Articles

Impact of targeting the platelet-activating factor and its receptor in cancer treatment.

Qaderi K, Shahmoradi A, Thyagarajan A, Sahu R Mil Med Res. 2025; 12(1):10.

PMID: 40033370 PMC: 11877967. DOI: 10.1186/s40779-025-00597-0.

Platelet-activating factor and protease-activated receptor 2 cooperate to promote neutrophil recruitment and lung inflammation through nuclear factor-kappa B transactivation.

Silva I, Almeida A, Lima Filho A, Fernandes-Braga W, Barra A, Oliveira H Sci Rep. 2023; 13(1):21637.

PMID: 38062077 PMC: 10703791. DOI: 10.1038/s41598-023-48365-1.

Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis.

Koumaki D, Gregoriou S, Evangelou G, Krasagakis K J Clin Med. 2023; 12(6).

PMID: 36983094 PMC: 10054239. DOI: 10.3390/jcm12062091.

Serum Levels of Eosinophil-Derived Neurotoxin, Platelet-Activating Factor and Vascular Endothelial Growth Factor in Adult Patients with Atopic Dermatitis-A Pilot Study.

Gomulka K, Wojcik E, Szepietowski J Biomedicines. 2022; 10(12).

PMID: 36551865 PMC: 9775762. DOI: 10.3390/biomedicines10123109.

Targeting the Platelet-Activating Factor Receptor (PAF-R): Antithrombotic and Anti-Atherosclerotic Nutrients.

Harishkumar R, Hans S, Stanton J, Grabrucker A, Lordan R, Zabetakis I Nutrients. 2022; 14(20).

PMID: 36297097 PMC: 9607086. DOI: 10.3390/nu14204414.

References

Terashita Z, Imura Y, Shino A, Nishikawa K . A lethal role of platelet activating factor in anaphylactic shock in mice. J Pharmacol Exp Ther. 1987; 243(1):378-83. View

Camerer E, Regard J, Cornelissen I, Srinivasan Y, Duong D, Palmer D . Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. J Clin Invest. 2009; 119(7):1871-9. PMC: 2701879. DOI: 10.1172/jci38575. View

Opal S, Laterre P, Abraham E, Francois B, Wittebole X, Lowry S . Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 2004; 32(2):332-41. DOI: 10.1097/01.CCM.0000108867.87890.6D. View

Schuster D, Metzler M, Opal S, Lowry S, Balk R, Abraham E . Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med. 2003; 31(6):1612-9. DOI: 10.1097/01.CCM.0000063267.79824.DB. View

Li S, Stuart L, Zhang Y, Meduri G, Umberger R, Yates C . Inter-individual variability of plasma PAF-acetylhydrolase activity in ARDS patients and PAFAH genotype. J Clin Pharm Ther. 2009; 34(4):447-55. DOI: 10.1111/j.1365-2710.2008.01014.x. View

Clark S, Ma A, Tavener S, McDonald B, Goodarzi Z, Kelly M . Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 2007; 13(4):463-9. DOI: 10.1038/nm1565. View

Zimmerman G . Plasma platelet-activating factor acetylhydrolase is a dynamic variable in critical illness: In the end, is change good for you?. Crit Care Med. 2005; 33(6):1462-3. DOI: 10.1097/01.ccm.0000166719.65161.d3. View

Mitsios J, Vini M, Stengel D, Ninio E, Tselepis A . Human platelets secrete the plasma type of platelet-activating factor acetylhydrolase primarily associated with microparticles. Arterioscler Thromb Vasc Biol. 2006; 26(8):1907-13. DOI: 10.1161/01.ATV.0000228821.79588.ef. View

Yost C, Cody M, Harris E, Thornton N, McInturff A, Martinez M . Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood. 2009; 113(25):6419-27. PMC: 2710935. DOI: 10.1182/blood-2008-07-171629. View

10.

Arai H, Koizumi H, Aoki J, Inoue K . Platelet-activating factor acetylhydrolase (PAF-AH). J Biochem. 2002; 131(5):635-40. DOI: 10.1093/oxfordjournals.jbchem.a003145. View

11.

Foulks J, Marathe G, Michetti N, Stafforini D, Zimmerman G, McIntyre T . PAF-acetylhydrolase expressed during megakaryocyte differentiation inactivates PAF-like lipids. Blood. 2009; 113(26):6699-706. PMC: 2710923. DOI: 10.1182/blood-2008-11-186312. View

12.

Poeze M, Froon A, Ramsay G, Buurman W, Greve J . Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock. 2000; 14(4):421-8. DOI: 10.1097/00024382-200014040-00001. View

13.

Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock D . Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008; 180(5):3478-84. DOI: 10.4049/jimmunol.180.5.3478. View

14.

Witzenrath M, Gutbier B, Owen J, Schmeck B, Mitchell T, Mayer K . Role of platelet-activating factor in pneumolysin-induced acute lung injury. Crit Care Med. 2007; 35(7):1756-62. DOI: 10.1097/01.CCM.0000269212.84709.23. View

15.

Zimmerman G, Weyrich A . Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol. 2008; 28(3):s17-24. PMC: 2594008. DOI: 10.1161/ATVBAHA.107.160218. View

16.

Vincent J, Spapen H, Bakker J, Webster N, Curtis L . Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med. 2001; 28(3):638-42. DOI: 10.1097/00003246-200003000-00006. View

17.

Lindemann S, Tolley N, Dixon D, McIntyre T, Prescott S, Zimmerman G . Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol. 2001; 154(3):485-90. PMC: 2196422. DOI: 10.1083/jcb.200105058. View

18.

Munford R . Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol. 2007; 1:467-96. DOI: 10.1146/annurev.pathol.1.110304.100200. View

19.

Claus R, Russwurm S, Dohrn B, Bauer M, Losche W . Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit Care Med. 2005; 33(6):1416-9. DOI: 10.1097/01.ccm.0000165807.26485.ed. View

20.

Marshall J . Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov. 2003; 2(5):391-405. DOI: 10.1038/nrd1084. View